Optimus Healthcare Services, Inc. Signs Memorandum of Understanding with RUA Diagnostics, Inc.
Optimus Healthcare Services, Inc. has entered into a Memorandum of Understanding with RUA Diagnostics, Inc. to negotiate a joint venture agreement for commercializing a diagnostic device based on a Patent License Agreement with the University of Michigan. The technology utilizes micro-gas chromatography and miniature gas detectors with AI software for breath analysis to diagnose diseases such as sepsis, ARDS, pneumonia, traumatic brain injury, and inflammatory diseases and cancers. The technology has shown promise in diagnosing COVID-19 and ARDS. The project has received funding from the Department of Defense and the National Institutes of Health.
08/16/2023 - 03:10 PM
NEW YORK, NY / ACCESSWIRE / August 16, 2023 / Optimus Healthcare Services, Inc. (OTC PINK:OHCS), announced today that it has entered into a Memorandum of Understanding with RUA Diagnostics, Inc., wherein the parties may negotiate a joint venture agreement for the purpose of commercializing a diagnostic device based on the Patent License Agreement ("Agreement") entered between RUA and the Regents of the University of Michigan. The Agreement includes dozens of U.S. and international patents regarding the use of micro-gas chromatography and miniature gas detectors used in conjunction with related software and artificial intelligence for breath analysis for the diagnosis of human and animal disease states. Initially, the targeted diseases for detection may include sepsis, ARDS (acute respiratory distress syndrome), pneumonia, traumatic brain injury, as well as other inflammatory diseases and cancers. In addition to disease detection, the technology enables the monitoring of the advancement of, or improvement of, the disease in the patient. The technology was developed in a collaboration between teams at the University of Michigan's College of Engineering and the Weil Institute for Critical Care Research and Innovation under the direction of Xudong Fan, PhD (Professor of Biomedical Engineering and Associate Director of the Weil Institute) and Kevin Ward, MD (Professor of Emergency Medicine and Director of the Weil Institute). The work the team has done to date has demonstrated the ability of the technology to diagnose patients with COVID-19 and ARDS. The work of the teams has been funded, in part, by the Department of Defense and the National Institutes of Health. The teams will continue their work on the advancement of this technology with RUA and Optimus.
About Optimus
Optimus Healthcare Services, Inc. is focused on creating a network of innovative healthcare companies that advance clinical research and disease management, provides access to vaccines and pharmaceuticals, and improves physician/patient interactions.
Caution Concerning Forward Looking Statements:
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not a guarantee of future actions or performance. These forward-looking statements are based on information currently available to Optimus and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning Optimus's business are described in Periodic and Current Reports filed with the Securities and Exchange Commission. Optimus is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Cliff Saffroncsaffron@theoptimushealthcare.com
SOURCE: Optimus HealthCare Services, Inc.
https://www.accesswire.com/774686/Optimus-Healthcare-Services-Inc-Signs-Memorandum-of-Understanding-with-RUA-Diagnostics-Inc
The joint venture agreement aims to commercialize a diagnostic device based on a Patent License Agreement with the University of Michigan.
The diagnostic device utilizes micro-gas chromatography, miniature gas detectors, and AI software for breath analysis.
The technology can diagnose diseases such as sepsis, ARDS, pneumonia, traumatic brain injury, inflammatory diseases, and cancers.
Yes, the technology has shown promise in diagnosing patients with COVID-19 and ARDS.
The project has received funding from the Department of Defense and the National Institutes of Health.
